Preclinical and translational data support EQ101 for the treatment of alopecia areata
Multiple cytokine inhibitors can provide a more selective and potent treatment approach than direct JAK inhibition
A phase 2 study of EQ101 in patients with alopecia areata to start in the fourth quarter of 2022
LA JOLLA, California, November 3, 2022–(COMMERCIAL WIRE)–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapies to treat serious autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 6the Annual dermatological drug development summit. The presentation highlights Equillium’s EQ101 multi-cytokine inhibitor as a novel molecular compound to treat alopecia areata. Dr. Stephen Connelly, Co-Founder and Chief Scientific Officer of Equillium, presented data on the first trispecific inhibitor in his class, targeting IL-2, IL-9 and IL-15. The Summit will take place at the Boston Park Plaza from November 1-3.
“Responsible for the signaling of more than 50 cytokines, the JAK/STAT pathways have become key targets for drug development, with multiple JAK inhibitors approved over the past decade. The problem, however, is that only a handful of these cytokines contribute to disease pathology, while the rest are physiologically important, leading to treatment-emergent toxicities and long-term safety concerns by regulators,” said Dr. Connelly. “EQ101 is a first-in-class trispecific cytokine inhibitor that selectively targets IL-2, IL-9 and IL-15 at the receptor level that may provide significant advantages over other approaches, including JAK inhibition. These Cytokines have been shown to be important in multiple dermatological diseases and with EQ101 previously achieving a favorable safety profile and clinical validation in the treatment of patients with cutaneous T-cell lymphoma, we hope to initiate a phase 2 clinical study in subjects with alopecia areata, very early”.
The presentation, titled “EQ101: A Multi-Specific Cytokine Inhibitor to Treat Alopecia Areata”, focuses on how the multi-cytokine inhibitor (MCi) platform has been used to target the common gamma receptor to generate EQ101. Early human studies of EQ101 were safe and well tolerated, while a previous phase 1/2 proof-of-concept study in cutaneous T-cell lymphoma (CTCL) demonstrated clinically significant improvement in skin scores. EQ101 was also shown to be more effective than ruxolitinib in hair regrowth and suppression of cytotoxic CD8+ T cells in an immune-mediated hair loss model. EQ101’s differentiated approach to blocking multiple cytokines at the receptor level may provide a more selective and potent treatment approach than direct JAK inhibition and may well position the molecule as an alternative or replacement for JAK inhibitors.
The presentation is available in the Multi-Cytokine tab of the Presentations in the Technology section of the company website.
About the Multi-Cytokine Platform: EQ101 and EQ102
Our proprietary Multi-Cytokine Platform (MCP) generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level and target pathogenic cytokine redundancies and synergies while preserving nonpathogenic signaling. This approach provides receptor-level inhibition of multiple cytokines and is expected to avoid the broad immunosuppression and off-target safety liabilities that may be associated with other therapeutic classes, such as JAK inhibitors. Many immune-mediated diseases are driven by the same combination of dysregulated cytokines, and we believe that identifying the key cytokines for these diseases will allow us to identify and develop personalized treatment strategies for multiple autoimmune and inflammatory diseases.
Current MCP assets include EQ101, a first-class, selective, trispecific inhibitor of IL-2, IL-9, and IL-15, and EQ102, a first-class, selective, bispecific inhibitor of IL-15 and IL-21. .
Equillium is a clinical-stage biotechnology company harnessing a deep understanding of immunobiology to develop novel therapies to treat serious autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel immunomodulatory actives that target immunoinflammatory pathways. Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway that plays a central role in modulating effector T cells, is currently in a phase 3 study for patients with acute graft disease. against host (aGVHD). ) and is in a phase 1b study for patients with lupus/lupus nephritis. EQ101 is a first-in-class trispecific cytokine inhibitor that selectively targets IL-2, IL-9 and IL-15. Equillium expects to begin enrolling patients in a phase 2 alopecia areata study of EQ101 in the fourth quarter of 2022. EQ102 is a bispecific cytokine inhibitor that selectively targets IL-15 and IL-21. Equinlium is currently enrolling patients in a phase 1 study of EQ102, including healthy volunteers and patients with celiac disease.
For more information visit www.equilliumbio.com.
Statements in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as ” anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “prospect”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are beyond the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the potential benefits of using our multi-cytokine platform to develop treatments for patients with certain autoimmune and inflammatory diseases, the Equillium plans, and the expected time to develop EQ101 and EQ102, including the expected timing of initiation, completion, and further announcement of results from the Phase 2 and Phase 1 studies, respectively, the potential for any of Equinlium’s planned or ongoing clinical studies to show safety or efficacy, the planned timing of Equillium for review and feedback, and Equinlium’s plans and expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of forward-looking statements include: uncertainties related to the abilities of the leadership team to perform as expected; Equinlium’s ability to execute its plans and strategies; risks related to conducting clinical studies; the risk that the interim results of a clinical study may not necessarily predict the final results and that one or more of the clinical outcomes may change materially as patient enrollment continues, after more extensive reviews of the data, and as has more patient data; potential delays in the initiation, enrollment, and completion of clinical trials and the reporting of clinical trial data; the risk that studies will not be completed as planned; Equillium’s product development and plans, including initiation and completion of clinical studies and reporting of data from clinical studies; whether the results of the clinical studies will validate and support the safety and efficacy of Equinlium’s product candidates; changes in the competitive landscape; uncertainties related to Equillium’s capital requirements; and having to use cash in different ways or at times than expected and the impact of market volatility on cash reserves. These and other risks and uncertainties are described in more detail under the heading “Risk Factors” and elsewhere in Equillium’s filings and reports, which can be accessed free of charge by visiting EDGAR on the SEC’s website at http://www.sec.gov and on the Company’s website under the heading “Investors”. Investors should be aware of such risks and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date they are made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date they are made.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20221103005508/en/
Vice President, Investor Relations and Corporate Communications